APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Hemolytic Uremic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Atypical Hemolytic Uremic Syndrome Drug Industry Research Report 2026

22 December 2025115 pages

Choose your research edition.

Industry ResearchAtypical Hemolytic Uremic Syndrome Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Hemolytic Uremic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Atypical Hemolytic Uremic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Hemolytic Uremic Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Hemolytic Uremic Syndrome Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Atypical Hemolytic Uremic Syndrome Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Atypical Hemolytic Uremic Syndrome Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Atypical Hemolytic Uremic Syndrome Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Atypical Hemolytic Uremic Syndrome Drug include Amgen Inc, Omeros Corp, Kedrion SpA, greenovation Biotech GmbH, ChemoCentryx Inc, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc and Achillion Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Atypical Hemolytic Uremic Syndrome Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Atypical Hemolytic Uremic Syndrome Drug Market by Company

Amgen Inc

Omeros Corp

Kedrion SpA

greenovation Biotech GmbH

ChemoCentryx Inc

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc

Atypical Hemolytic Uremic Syndrome Drug Segment by Type

OMS-72

Mubodina

ETR-001

ET-006

CCX-168

ALN-CC5

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Application

Clinic

Hospital

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Hemolytic Uremic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Hemolytic Uremic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Hemolytic Uremic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Atypical Hemolytic Uremic Syndrome Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Atypical Hemolytic Uremic Syndrome Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Atypical Hemolytic Uremic Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Atypical Hemolytic Uremic Syndrome Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Atypical Hemolytic Uremic Syndrome Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Atypical Hemolytic Uremic Syndrome Drug Revenue of Manufacturers (2021-2026) Table 9. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Atypical Hemolytic Uremic Syndrome Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Atypical Hemolytic Uremic Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Product Type & Application Table 14. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Atypical Hemolytic Uremic Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amgen Inc Company Information Table 19. Amgen Inc Business Overview Table 20. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 22. Amgen Inc Recent Developments Table 23. Omeros Corp Company Information Table 24. Omeros Corp Business Overview Table 25. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 27. Omeros Corp Recent Developments Table 28. Kedrion SpA Company Information Table 29. Kedrion SpA Business Overview Table 30. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 32. Kedrion SpA Recent Developments Table 33. greenovation Biotech GmbH Company Information Table 34. greenovation Biotech GmbH Business Overview Table 35. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 37. greenovation Biotech GmbH Recent Developments Table 38. ChemoCentryx Inc Company Information Table 39. ChemoCentryx Inc Business Overview Table 40. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 42. ChemoCentryx Inc Recent Developments Table 43. Alexion Pharmaceuticals Inc Company Information Table 44. Alexion Pharmaceuticals Inc Business Overview Table 45. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 47. Alexion Pharmaceuticals Inc Recent Developments Table 48. Akari Therapeutics Plc Company Information Table 49. Akari Therapeutics Plc Business Overview Table 50. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 52. Akari Therapeutics Plc Recent Developments Table 53. Achillion Pharmaceuticals Inc Company Information Table 54. Achillion Pharmaceuticals Inc Business Overview Table 55. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 57. Achillion Pharmaceuticals Inc Recent Developments Table 58. Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026) & (k units) Table 60. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2026) Table 61. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2027-2032) & (k units) Table 62. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2027-2032) Table 63. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2026) Table 65. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2027-2032) Table 67. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 69. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 70. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 74. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 75. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 84. South America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 85. South America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 93. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 94. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2026) Table 95. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2027-2032) Table 96. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2026) Table 99. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2027-2032) Table 100. Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2026) & (US$/unit) Table 101. Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2027-2032) & (US$/unit) Table 102. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 103. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 104. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2026) Table 105. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2027-2032) Table 106. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2026) Table 109. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2027-2032) Table 110. Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2026) & (US$/unit) Table 111. Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Atypical Hemolytic Uremic Syndrome Drug Distributors List Table 115. Atypical Hemolytic Uremic Syndrome Drug Customers List Table 116. Atypical Hemolytic Uremic Syndrome Drug Industry Trends Table 117. Atypical Hemolytic Uremic Syndrome Drug Industry Drivers Table 118. Atypical Hemolytic Uremic Syndrome Drug Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Atypical Hemolytic Uremic Syndrome Drug Product Image Figure 5. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Atypical Hemolytic Uremic Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Atypical Hemolytic Uremic Syndrome Drug Sales (2021-2032) & (k units) Figure 8. Global Atypical Hemolytic Uremic Syndrome Drug Average Price (US$/unit) & (2021-2032) Figure 9. OMS-72 Product Image Figure 10. Mubodina Product Image Figure 11. ETR-001 Product Image Figure 12. ET-006 Product Image Figure 13. CCX-168 Product Image Figure 14. ALN-CC5 Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. Others Product Image Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Atypical Hemolytic Uremic Syndrome Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region in 2025 Figure 25. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region in 2025 Figure 26. North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country in 2025 Figure 27. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 28. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Country in 2025 Figure 33. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Country in 2025 Figure 46. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 48. China Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country in 2025 Figure 57. South America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 58. South America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Atypical Hemolytic Uremic Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032) Figure 71. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Atypical Hemolytic Uremic Syndrome Drug Price (US$/unit) by Type (2021-2032) Figure 73. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032) Figure 74. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Atypical Hemolytic Uremic Syndrome Drug Price (US$/unit) by Application (2021-2032) Figure 76. Atypical Hemolytic Uremic Syndrome Drug Value Chain Figure 77. Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • OMS-72
  • Mubodina
  • ETR-001
  • ET-006
  • CCX-168
  • ALN-CC5
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Amgen Inc
  • Omeros Corp
  • Kedrion SpA
  • greenovation Biotech GmbH
  • ChemoCentryx Inc
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Achillion Pharmaceuticals Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size (2021-2032)
  4. 2.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales (2021-2032)
  5. 2.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Market Average Price (2021-2032)
  6. 2.3 Atypical Hemolytic Uremic Syndrome Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 OMS-72
  9. 2.3.3 Mubodina
  10. 2.3.4 ETR-001
  11. 2.3.5 ET-006
  12. 2.3.6 CCX-168
  13. 2.3.7 ALN-CC5
  14. 2.3.8 Others
  15. 2.4 Atypical Hemolytic Uremic Syndrome Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Atypical Hemolytic Uremic Syndrome Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Atypical Hemolytic Uremic Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Atypical Hemolytic Uremic Syndrome Drug, Established Date
  9. 3.9 Global Atypical Hemolytic Uremic Syndrome Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amgen Inc
  2. 4.1.1 Amgen Inc Company Information
  3. 4.1.2 Amgen Inc Business Overview
  4. 4.1.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  6. 4.1.5 Amgen Inc Recent Developments
  7. 4.2 Omeros Corp
  8. 4.2.1 Omeros Corp Company Information
  9. 4.2.2 Omeros Corp Business Overview
  10. 4.2.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  12. 4.2.5 Omeros Corp Recent Developments
  13. 4.3 Kedrion SpA
  14. 4.3.1 Kedrion SpA Company Information
  15. 4.3.2 Kedrion SpA Business Overview
  16. 4.3.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  18. 4.3.5 Kedrion SpA Recent Developments
  19. 4.4 greenovation Biotech GmbH
  20. 4.4.1 greenovation Biotech GmbH Company Information
  21. 4.4.2 greenovation Biotech GmbH Business Overview
  22. 4.4.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  24. 4.4.5 greenovation Biotech GmbH Recent Developments
  25. 4.5 ChemoCentryx Inc
  26. 4.5.1 ChemoCentryx Inc Company Information
  27. 4.5.2 ChemoCentryx Inc Business Overview
  28. 4.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  30. 4.5.5 ChemoCentryx Inc Recent Developments
  31. 4.6 Alexion Pharmaceuticals Inc
  32. 4.6.1 Alexion Pharmaceuticals Inc Company Information
  33. 4.6.2 Alexion Pharmaceuticals Inc Business Overview
  34. 4.6.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  36. 4.6.5 Alexion Pharmaceuticals Inc Recent Developments
  37. 4.7 Akari Therapeutics Plc
  38. 4.7.1 Akari Therapeutics Plc Company Information
  39. 4.7.2 Akari Therapeutics Plc Business Overview
  40. 4.7.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  42. 4.7.5 Akari Therapeutics Plc Recent Developments
  43. 4.8 Achillion Pharmaceuticals Inc
  44. 4.8.1 Achillion Pharmaceuticals Inc Company Information
  45. 4.8.2 Achillion Pharmaceuticals Inc Business Overview
  46. 4.8.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  48. 4.8.5 Achillion Pharmaceuticals Inc Recent Developments
5 Global Atypical Hemolytic Uremic Syndrome Drug Market Scenario by Region
  1. 5.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2027-2032
  5. 5.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2027-2032
  8. 5.4 North America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
  9. 5.4.1 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
  41. 5.7.1 South America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Atypical Hemolytic Uremic Syndrome Drug Value Chain Analysis
  2. 8.1.1 Atypical Hemolytic Uremic Syndrome Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process
  5. 8.2 Atypical Hemolytic Uremic Syndrome Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
  8. 8.2.3 Atypical Hemolytic Uremic Syndrome Drug Customers
9 Global Atypical Hemolytic Uremic Syndrome Drug Analyzing Market Dynamics
  1. 9.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
  2. 9.2 Atypical Hemolytic Uremic Syndrome Drug Industry Drivers
  3. 9.3 Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges
  4. 9.4 Atypical Hemolytic Uremic Syndrome Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst